Recombinant vaccinia virus derived from KVAC103 strain

• US 9,879,281 B2
• Filed: 10/15/2015
• Issued: 01/30/2018
• Est. Priority Date: 10/16/2014
• Status: Active Grant

• Current Assignee: Korea Center For Disease Control and Prevention
• Original Assignee: Korea Center For Disease Control and Prevention
• Inventors: Son, Ho Sun, Yeo, Sang Gu, Lee, Sang Won
• Primary Examiner(s): Andres, Janet L
• Assistant Examiner(s): SNYDER, STUART
• Application Number:
  US14/883,752
• Publication Number:
  US 20160108371A1
• Time in Patent Office: 838 Days
• Field of Search: None
• CPC Class Codes: A61K 39/07 Bacillus
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/24121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
• CPC Class Codes: C12N 2710/24134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2710/24143 viral genome or elements thereof as genetic vector

Abstract

Disclosed herein is a novel recombinant virus vector derived from the attenuated vaccinia virus strain KVAC103. The recombinant virus vector is obtained by inserting an exogenous gene into the KVAC103 and may be used as a safe vaccine delivery vehicle in mammals. Particularly, recombinant viruses obtained by rescuing some of the genes deleted from the parent virus have an enhanced ability to proliferate in cells being cultured, and thus are easily produced. In addition, the recombinant viruses express an increased level of an exogenous antigen, and thus has enhanced immunogenic efficacy. Such recombinant virus vectors may be used in vaccines for preventing diseases, therapeutic vaccines, and molecular biological studies.

Claims

1. A recombinant vaccinia virus comprising a heterologous polynucleotide inserted into a thymidine kinase (tk) gene locus of a genome of attenuated vaccinia virus KVAC103 (accession No. KCCM11574P), wherein the heterologous polynucleotide encodes at least one protein.

2. The recombinant vaccinia virus of claim 1, wherein the heterologous polynucleotide comprises a polynucleotide encoding a fluorescent protein, a polynucleotide encoding an antigen, a polynucleotide represented by SEQ ID NO:

2, a polynucleotide represented by SEQ ID NO;

3, or a combination thereof.

3. A vaccine composition containing the recombinant vaccinia virus of claim 2.

4. A vaccine composition containing the recombinant vaccinia virus of claim 1.

5. A method for constructing a recombinant vaccinia virus comprising a heterologous polynucleotide, the method comprising the steps of:

A) Inserting the heterologous polynucleotide into a restriction site of a plasmid vector for producing a recombinant vaccinia virus; and

B) inserting the heterologous polynucleotide, inserted into the plasmid vector in step A, into the thymidine kinase gene locus of a genome of attenuated vaccinia virus KVAC103 by homologous recombination;

wherein the heterologous polynucleotide encodes at least one protein, and

wherein the heterologous polynucleotide comprises a polynucleotide encoding a fluorescent protein, a polynucleotide encoding an antigen, a polynucleotide represented by SEQ ID NO;

2, a polynucleotide represented by SEQ ID NO;

3, or a combination thereof.

6. The method of claim 5, wherein the plasmid vector is represented by SEQ ID NO:

1.

7. The method of claim 5, wherein the plasmid vector comprises:

A thymidine kinase (tk) gene locus sequence of attenuated vaccinia virus KVAC103 (accession No. KCCM11574P),

an ampicillin resistance gene,

a replication origin,

an early-to-late promoter,

a multicloning site (MCS) sequence, and

a polynucleotide encoding an enhanced green fluorescent protein (EGFP).